Activation of Resting Human B Cells by Helper T-Cell Clone Supernatant

Total Page:16

File Type:pdf, Size:1020Kb

Activation of Resting Human B Cells by Helper T-Cell Clone Supernatant Proc. Nati. Acad. Sci. USA Vol. 84, pp. 9140-9144, December 1987 Immunology Activation of resting human B cells by helper T-cell clone supernatant: Characterization of a human B-cell-activating factor (T-celi lymphokines/B-ceil stimulation) ANITA DIu*, MARIE-LISE GOUGEON*, JEAN-LOUIS MOREAU*, ELLIS L. REINHERZt, AND JACQUES THtZE* *Unitd d'Immunogdndtique Cellulaire, Institut Pasteur, 25, rue du Docteur Roux 75015 Paris, France; and tDivision of Immunobiology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115 Communicated by Baruj Benacerraf, August 17, 1987 ABSTRACT The effects of helper T-cell clone superna- (Pharmacia, Paris) density-gradient centrifugation of periph- tants on resting human B cells were investigated. Four different eral blood from healthy adult volunteers and were partially helper T-cell clones (two T4' and two T8+) were stimulated by depleted of adherent cells by adherence to plastic culture anti-T3 monoclonal antibodies on Sepharose beads or anti-T112 dishes. Nonadherent cells were submitted to rosette forma- plus anti-T113 monoclonal antibodies. The supernatants from tion with neuraminidase-treated sheep erythrocytes, and these activated clones induced the proliferation of highly nonrosetting cells were recovered after centrifugation on a purified resting B lymphocytes from the peripheral blood. The Lymphoprep gradient (Nyegaard, Oslo). The B cells were B cells exhibited a cell size and a surface-antigen pattern (4F2 then separated by using a discontinuous gradient of Percoll antigen and transferrin receptor) of phase Go B cells, and they (Pharmacia) as described (12), and cells banding at the were functionally resting. In response to T-cell supernatants a interface between Percoll concentrations 50o and 60% were large fraction of the B cells enlarged and expressed 4F2 collected. These preparations (referred to as dense B cells) antigens and transferrin receptors. In gel filtration, the cor- routinely contained <1% T cells, 2-3% monocytes, and responding activity migrated with an apparent Mr of 12,000- >85% B cells as determined by immunofluorescence staining 15,000. Our fwdings strongly support the existence ofa human using anti-T4 plus anti-T8, MO1, and anti-Bi mAbs, respec- B-cell-activating factor acting on resting B cells and causing tively (21, 22). The B-cell preparations showed no prolifer- them to enter phase G1 of the cell cycle. ative response to T-cell mitogens such as phytohemagglutinin (PHA), concanavalin A, or anti-T112 plus anti-T113 mAbs. In T-cell-dependent responses, specific T-cell-B-cell contact Dense B cells (5 x 104 per well) were cultured in 96-well is supposed to control B-cell activation, whereas later stages round-bottomed microtiter plates (Costar, Cambridge, MA) of B-cell maturation are driven by nonspecific T-cell-derived in 200-,lI final volume in RPMI 1640 medium (M.A. Bio- lymphokines (1, 2). In the human model, B-cell proliferation products, Walkersville, MD) containing 10% fetal calf serum is mediated by two B-cell growth factors (BCGF): a low-Mr (Flow Laboratories, Paris), 1 mM L-glutamine, 1% penicil- and a high-Mr BCGF (3-5). Human interleukin 4 (IL-4) also lin/streptomycin, and 10 mM Hepes. Thymidine uptake was acts as a B-cell proliferative factor (6). In vitro assays for the measured after 3 days of culture with a 16-hr exposure to 1 detection of these lymphokines involve submitogenic con- ,uCi of [3H]thymidine per well (1 Ci = 37 GBq). centrations of anti-, heavy chain immunoglobulin (anti-,) T-Cell Clones. P2 and N2 (T8+) were cloned twice by antibodies or Staphylococcus aureus Cowan A strain (SAC) limiting dilution methods, in which T cells from a healthy that are supposed to polyclonally activate resting B cells. volunteer (0.3 cell per well) were plated in the presence of Interleukin 2 (IL-2) also induces proliferation and, in some irradiated autologous feeder layers in IL-2-containing medi- cases, differentiation of SAC or anti-,-activated human B um with 0.25 ,ug of PHA per ml (Wellcome). Tetanus cells (7). In addition, a direct effect ofvery high doses ofIL-2 toxoid-specific T-cell clones TT1 and TT9 (T4+) were ob- on unstimulated B cells (8) was also reported. tained in the same way from an antigen-specific cell line In the mouse model, we have shown that the T cells can be raised from T cells ofa healthy volunteer using tetanus toxoid replaced by their supernatant for mouse resting B-cell acti- at 0.3 floculation unit/ml (Massachusetts State Biological vation, proliferation, and differentiation (9-11). We have Laboratories, Jamaica Plain, MA). T cells were cultured in hypothesized that a new lymphokine called B-cell-activating IL-2-containing medium. Restimulation was done every 4 factor (BCAF) was responsible for resting B-cell activation, weeks in the presence of irradiated feeder cells, PHA (0.25 and we now have evidence that this factor is distinct from ,tg/ml), and IL-2. The T-cell cultures tested negatively for other mouse lymphokines. In this report, we extend these mycoplasma at least twice during the course of this work. observations to the human model. Using helper T-cell clones Production ofT-Cell Supernatants. T-cell clones were taken stimulated by anti-T3 or anti-T11 monoclonal antibodies 15 days after restimulation, washed once, and incubated in 5 (mAbs), we have produced supernatants that could polyclon- ml of polypropylene tubes (Falcon) at 106 cells/ml for 6 hr or ally activate highly purified resting human B cells from the 24 hr at 37°C in medium alone, or in the presence of anti-T3 peripheral blood. Our findings strongly support the existence mAbs on Sepharose beads (1/50) (13), or a combination of of a human BCAF with an apparent Mr of 12,000- anti-T112 plus anti-T113 mAbs (1/200 dilution of ascitic fluid) 15,000. (14). The supernatants were then collected, filtered through a 0.22-,um Millipore membrane, and used immediately or MATERIALS AND METHODS stored at -20°C. B-Cell Preparation and Proliferation Assay. Peripheral blood mononuclear cells were obtained by Ficoll/Hypaque Abbreviations: anti-A, anti-, heavy chain immunoglobulin antibod- ies; BCAF, B-cell-activating factor; BCGF, B-cell growth factor; IL-2, interleukin 2; IL-4, interleukin 4; mAb, monoclonal antibody; The publication costs of this article were defrayed in part by page charge PHA, phytohemagglutinin; P2(T11)-SN, P2(T11) supernatant; FITC, payment. This article must therefore be hereby marked "advertisement" fluorescein isothiocyanate; SAC, Staphylococcus aureus Cowan A in accordance with 18 U.S.C. §1734 solely to indicate this fact. strain. 9140 Downloaded by guest on September 26, 2021 Immunology: Diu et al. Proc. Natl. Acad. Sci. USA 84 (1987) 9141 RESULTS IL-2 Is not Involved in the B-Cell Response to T-Cell Supernatant. Because high doses of IL-2 were able to induce Supernatants from Activated T-Cell Clones Aire Sufficient to some proliferation of resting B cells and because T-cell Induce the Proliferation of Unstimulated B Ccells. Two T4' supernatants did contain some IL-2 (as measured on an T-cell clones (TT1 and TT9) and two T8' clone1s (P2 and N2) IL-2-dependent T-cell line), it was of interest to evaluate the were activated for 24 hr by anti-T3 mAbs 4on Sepharose contribution of IL-2 to our results. The final concentration of beads, or by a combination of anti-T112 and aniti-T113 mAbs. IL-2 from P2(Tll)-SN in the B-cell assays (between 0.6 and The culture supernatants were collected and as&sayed in B-cell 1.25 ng/ml) was too low to account by itselffor the observed cultures. As shown in Fig. 1, dense B cells are driven to response (Table 1). We further excluded the participation of proliferate in response to these helper T-cell suipernatants, in IL-2 in the effects ofthe T-cell supernatant by either blocking the absence of any other added stimulus, andI this effect is the IL-2 receptor or neutralizing the IL-2 activity with dose dependent. The release of this proliferrative activity appropriate mAbs. As shown in Table 2, when resting B cells needs stimulation of the T-cell clones becauwse little or no were cultured with anti-pt and recombinant IL-2, both 33B3-1 activity is detectable in supernatants from uinstimulated T (anti-IL-2R IgG2a, ref. 15) and DMS-1 (anti-IL-2 IgG1, ref. cells. In addition, the proliferation of B cellIs induced by 16) mAbs were able to inhibit the B-cell response to IL-2. On T-cell supernatant is not major histocompatiboility complex- the contrary, the response to P2(T11)-SN was not signifi- iit comf cantly affected by either mAb. As a control, we checked that restricted. Supernatants obtained after stimul o ploex 33B3-1 and DMS-1 mAbs did not affect the BCGF-induced P2 with anti-T112 plus anti-T113 mAbs [P2(Ta11tSN'11)-SN] weree response of anti-,u activated B cells (data not shown). studied in greater detail. Size Analysis of Resting B Cells Stimulated with P2(Tll)-SN. The Responding B-Cell Population Consists c sf Functionally The change in size of small B cells was analyzed at different Resting B Cells. The B cells used in the culturels consisted of times after stimulation with P2(T11)-SN. Fig. 2 shows that at dense B cells with a mean volume correspondling to cells in initiation of the culture, Percoll gradient-purified B cells phase Go of the cell cycle (Fig. 2A). To verify Ithat they were exhibited a mean cell volume ranging between 140 and 160 also functionally resting and to exclude that our results could ,1Mm3.
Recommended publications
  • Expression of the Alpha, Beta, and Gamma Subunits of the Interleukin-2
    Expression of the Alpha, Beta, and Gamma Subunits of the Interleukin-2 Receptor by Human Vascular Smooth Muscle Cells A thesis submitted in partial fulfillment Of the requirements for the degree of Master of Science By Sultan Alhayyani B.S. King Abdulaziz University 2014 Wright State University WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES April 14, 2014 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SULTAN ALHAYYANI ENTITLED EXPRESSION OF THE ALPHA, BETA, AND GAMMA SUBUNITS OF THE INTERLEUKIN-2 RECEPTOR BY HUMAN VASCULAR SMOOTH MUSCLE CELLS BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science. Lucile Wrenshall, MD, Ph.D. Thesis Director Committee on Final Examination Lucile Wrenshall, MD, Ph.D. Barbara E. Hull, Ph.D. Professor of Neuroscience, Cell Biology, and Director of Microbiology and Physiology Immunology Program, College of Science and Mathematics Barbara E. Hull, Ph.D. Professor of Biological Sciences Nancy J. Bigley, Ph.D. Professor of Microbiology and Immunology John Miller, Ph.D. Adjunct Assistant Professor Of Neuroscience, Cell Biology, and Physiology Robert E. W. Fyffe, Ph.D. Vice President of Research and Dean of the Graduate School ABSTRACT Alhayyani, Sultan. M.S. Microbiology and Immunology Graduate Program, Wright State University, 2014. Expression of the Alpha, Beta, and Gamma Subunits of the Interleukin-2 Receptor by Human Vascular Smooth Muscle Cells. Interleukin 2 (IL-2) is a member of the cytokine family and contributes to the proliferation, survival, and death of lymphocytes [1]. The interleukin-2 receptor (IL-2) is a tripartite receptor commonly expressed on the surfaces of many lymphoid cells and is composed of three non-covalently associated subunits, alpha (α) (CD25), beta (β) (CD122), and gamma (γ) (CD132) [2].
    [Show full text]
  • Interleukin 2 Medical Intensive Care Unit (4MICU)
    Interleukin 2 Medical Intensive Care Unit (4MICU) Ronald Reagan UCLA Medical Center 757 Westwood Plaza Los Angeles, CA 90095 Main Phone: (310) 267-7441 Fax: (310) 267-3785 About Our Unit The Medical Intensive Care Unit (MICU) cares Quick for critically ill patients in an intensive care Reference Guide environment, with nursing staff specially trained in the administration of Interleukin 2 therapy. Unit Director / Manager Mark Flitcraft, RN, MSN One registered nurse (RN) is assigned to take (310) 267-9529 care of a maximum of two patients. Our Medical Clinical Nurse Specialist Intensive Care Unit patient rooms are designed Yuhan Kao, RN, MSN, CNS (310) 267-7465 to allow nurses constant visual contact with their patients. As a safety precaution, the Medical Assistant Manager Sherry Xu, RN, BA, CCRN Intensive Care Unit is a closed unit and requires (310) 267-7485 permission to enter by intercom. Clinical Case Manager Each private-patient-care room contains the Connie Lefevre (310) 267-9740 most advanced intensive-care equipment available, including cardiac-monitoring and Clinical Social Worker Codie Lieto emergency-response equipment. The curtains in (310) 267-9741 the room will usually be drawn to keep your room Charge Nurse On-Duty more private. (310) 267-7480 or (310) 267-7482 A brief tour is available on weekdays for patients and visitors interested in walking through the unit Patient Affairs (310) 267-9113 and meeting the staff before arrival. To arrange for a tour, please call the nurse manager at Respiratory Supervisor (310) 267-9529. Orna Molayeme, MA, RCP, RRT, NPS (310) 267-8921 UCLAHEALTH.ORG 1-800-UCLA-MD1 (1-800-825-2631) About Our Unit During Your Stay Quick The Medical Team Reference Guide During each shift, you will be assigned a registered nurse (RN) and a clinical care partner (CCP).
    [Show full text]
  • Levels of Interleukin-2, Interferon- , and Interleukin-4 In
    Levels of Interleukin-2, Interferon-␥, and Interleukin-4 in Bronchoalveolar Lavage Fluid From Patients With Mycoplasma Pneumonia: Implication of Tendency Toward Increased Immunoglobulin E Production Young Yull Koh, MD*; Yang Park, MD*; Hoan Jong Lee, MD*; and Chang Keun Kim, MD‡ ABSTRACT. Objective. In connection with the possi- ABBREVIATIONS. IgE, immunoglobulin E; TH1, T helper type 1; ble relationship between Mycoplasma infection and the TH2, T helper type 2; IFN, interferon; IL, interleukin; BAL, bron- onset of asthma, several studies have shown not only a choalveolar lavage; FB, fiber-optic bronchoscopy; SD, standard high level of serum total immunoglobulin E (IgE) but deviation. also the production of IgE specific to Mycoplasma or common allergens during the course of Mycoplasma in- fection. It has been suggested that the balance of T helper esults of several studies over the past decade type 1 (TH1)/T helper type 2 (TH2) immune response have provided evidence linking Mycoplasma may regulate the synthesis of IgE. The objective of this Rinfection with asthma exacerbation and have study was to investigate the pattern of cytokine response raised the possibility that Mycoplasma infection is a (TH1 or TH2) during an episode of acute lower respira- factor in the pathogenesis of asthma. An acute exac- tory tract infection caused by Mycoplasma pneumoniae. erbation of wheezing in asthmatic participants in Study Design. Using a bronchoalveolar lavage (BAL) association with Mycoplasma infection has been well- with flexible bronchoscopy procedure, this study deter- 1,2 mined the levels of interleukin (IL)-2, interferon (IFN)-␥ documented. In addition, Mycoplasma pneumoniae (TH1), and IL-4 (TH2) in the supernatant of BAL fluid as has been found in the lower airways of chronic, well as the BAL cellular profiles of patients with Myco- stable asthmatics with a greater frequency than in -These results were com- control participants,3 suggesting a pathogenic mech .(14 ؍ plasma pneumonia (n pared with those of patients with pneumococcal pneu- anism in chronic asthma.
    [Show full text]
  • Modulation of the Inflammatory Response After Spinal Cord Injury
    ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en MODULATION OF THE INFLAMMATORY RESPONSE AFTER SPINAL CORD INJURY Presented by Jesús Amo Aparicio ACADEMIC DISSERTATION To obtain the degree of PhD in Neuroscience by the Universitat Autònoma de Barcelona 2019 Directed by Dr. Rubèn López Vales Tutorized by Dr. Xavier Navarro Acebes INDEX SUMMARY Page 7 INTRODUCTION Page 13 - Spinal cord Page 15 - Spinal cord injury Page 17 - Incidence and causes Page 18 - Types of SCI Page 18 - Biological events after SCI Page 20 - Studying SCI Page 24 - Animal models Page 24 - Lesion models Page 24 - Current therapies for SCI Page 25 - Basic principles of the immune system Page 27 - Innate immune response Page 27 - Adaptive immune response Page 28 - Inflammatory response Page 29 - Inflammatory response after SCI Page 30 - Modulation of injury environment Page 36 - Interleukin 1 Page 36 - Interleukin 37 Page 40 - Interleukin 13 Page 44 OBJECTIVES Page 47 MATERIALS AND METHODS Page 51
    [Show full text]
  • IL-1Β Induces the Rapid Secretion of the Antimicrobial Protein IL-26 From
    Published June 24, 2019, doi:10.4049/jimmunol.1900318 The Journal of Immunology IL-1b Induces the Rapid Secretion of the Antimicrobial Protein IL-26 from Th17 Cells David I. Weiss,*,† Feiyang Ma,†,‡ Alexander A. Merleev,x Emanual Maverakis,x Michel Gilliet,{ Samuel J. Balin,* Bryan D. Bryson,‖ Maria Teresa Ochoa,# Matteo Pellegrini,*,‡ Barry R. Bloom,** and Robert L. Modlin*,†† Th17 cells play a critical role in the adaptive immune response against extracellular bacteria, and the possible mechanisms by which they can protect against infection are of particular interest. In this study, we describe, to our knowledge, a novel IL-1b dependent pathway for secretion of the antimicrobial peptide IL-26 from human Th17 cells that is independent of and more rapid than classical TCR activation. We find that IL-26 is secreted 3 hours after treating PBMCs with Mycobacterium leprae as compared with 48 hours for IFN-g and IL-17A. IL-1b was required for microbial ligand induction of IL-26 and was sufficient to stimulate IL-26 release from Th17 cells. Only IL-1RI+ Th17 cells responded to IL-1b, inducing an NF-kB–regulated transcriptome. Finally, supernatants from IL-1b–treated memory T cells killed Escherichia coli in an IL-26–dependent manner. These results identify a mechanism by which human IL-1RI+ “antimicrobial Th17 cells” can be rapidly activated by IL-1b as part of the innate immune response to produce IL-26 to kill extracellular bacteria. The Journal of Immunology, 2019, 203: 000–000. cells are crucial for effective host defense against a wide and neutrophils.
    [Show full text]
  • The Cross-Talk Between Neurons and Microglia Through Interleukin-4 After Ischemic Injury
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 8-2018 The Cross-Talk Between Neurons and Microglia Through Interleukin-4 After Ischemic Injury Shun-Ming Ting Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Medicine and Health Sciences Commons Recommended Citation Ting, Shun-Ming, "The Cross-Talk Between Neurons and Microglia Through Interleukin-4 After Ischemic Injury" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 892. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/892 This Thesis (MS) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. THE CROSS-TALK BETWEEN NEURONS AND MICROGLIA THROUGH INTERLEUKIN-4 AFTER ISCHEMIC INJURY by Shun-Ming Ting, M.S. APPROVED: ______________________________ Jaroslaw Aronowski, Ph.D. Advisory
    [Show full text]
  • Evolutionary Divergence and Functions of the Human Interleukin (IL) Gene Family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W
    UPDATE ON GENE COMPLETIONS AND ANNOTATIONS Evolutionary divergence and functions of the human interleukin (IL) gene family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W. Nebert3* and Vasilis Vasiliou1 1Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA 2Department of Clinical Pharmacy, University of Colorado Denver, Aurora, CO 80045, USA 3Department of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, OH 45267–0056, USA *Correspondence to: Tel: þ1 513 821 4664; Fax: þ1 513 558 0925; E-mail: [email protected]; [email protected] Date received (in revised form): 22nd September 2010 Abstract Cytokines play a very important role in nearly all aspects of inflammation and immunity. The term ‘interleukin’ (IL) has been used to describe a group of cytokines with complex immunomodulatory functions — including cell proliferation, maturation, migration and adhesion. These cytokines also play an important role in immune cell differentiation and activation. Determining the exact function of a particular cytokine is complicated by the influence of the producing cell type, the responding cell type and the phase of the immune response. ILs can also have pro- and anti-inflammatory effects, further complicating their characterisation. These molecules are under constant pressure to evolve due to continual competition between the host’s immune system and infecting organisms; as such, ILs have undergone significant evolution. This has resulted in little amino acid conservation between orthologous proteins, which further complicates the gene family organisation. Within the literature there are a number of overlapping nomenclature and classification systems derived from biological function, receptor-binding properties and originating cell type.
    [Show full text]
  • Expression of Interleukin-4 but Not of Interleukin-10 from a Replicative Herpes Simplex Virus Type 1 Viral Vector Precludes Experimental Allergic Encephalomyelitis
    Gene Therapy (2001) 8, 769–777 2001 Nature Publishing Group All rights reserved 0969-7128/01 $15.00 www.nature.com/gt RESEARCH ARTICLE Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis E Broberg1,2,3, N Seta¨la¨ 1,3,MRo¨ytta¨4, A Salmi1, J-P Era¨linna1,5,BHe6, B Roizman6 and V Hukkanen1,2 Departments of 1Virology, 4Pathology, 5Neurology and 2MediCity Research Laboratory, University of Turku, Turku; 3Turku Graduate School of Biomedical Sciences, Turku, Finland; and 6The Marjorie B Kovler Viral Oncology Laboratories, University of Chicago, Chicago, IL, USA We have used interleukin (IL)-4 and -10-producing HSV-1 any infection, mice infected with backbone virus R3659 and ␥ 134.5 deletion viruses in gene therapy of a BALB/c model mock-infected mice. Weights and symptoms of the mice of experimental allergic encephalomyelitis (EAE), a T cell- were recorded daily and the tissue specimens were col- mediated demyelinating disease of the central nervous sys- lected at specific time-points. The results indicate that the tem. It is known that in EAE of mice the Th2-type cytokines intracranial infection with IL-4-producing virus (1) precludes are down-regulated and the Th1-type cytokines up-regulated EAE symptoms, (2) protects the spinal cord from massive during the onset and relapse of the disease. Therefore, we leukocyte infiltrations and (3) prevents demyelination and tested two HSV-1 recombinants expressing the Th2-type axonal loss. The IL-10-expressing virus R8308 did not have cytokines IL-4 and IL-10.
    [Show full text]
  • IL-1/IL-3 Gene Therapy of Non-Small Cell Lung Cancer (NSCLC) in Rats Using ‘Cracked’ Adenoproducer Cells
    Gene Therapy (1998) 5, 778–788 1998 Stockton Press All rights reserved 0969-7128/98 $12.00 http://www.stockton-press.co.uk/gt IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using ‘cracked’ adenoproducer cells MC Esandi1,2, GD van Someren1, A Bout3, AH Mulder4, DW van Bekkum3, D Valerio1,3 and JL Noteboom1,5 1Section Gene Therapy, Department of Molecular Cell Biology, Leiden University; 3IntroGene BV, Leiden; and 4Pathologisch Laboratorium, Dordrecht, The Netherlands Cytokine gene therapy was studied in established L42 tumour responses. These were due to local release of cyto- tumours in syngeneic rats. L42 is a transplantable non- kines, not to systemic effects. Growth retardation also immunogenic non-small cell lung cancer (NSCLC). Genes occurred in contralateral tumours which were not injected. coding for human interleukin-1␣ and for rat interleukin-3␤ When rats carrying established tumours were vaccinated were transferred by injecting producer cells of recombinant with lysates of tumours collected during treatment with adenovirus vectors into the tumour in attempts to achieve ‘cracked’ producer cells, significant tumour growth retar- high concentrations of the cytokines inside the tumor with- dation was obtained. We speculate that both cytokines, if out systemic toxicity. Limited tumour growth delay was produced at sufficiently high concentrations in tumours, obtained with viable producer cells. For logistic reasons induce inflammation which in turn initiates an immune stocks of pooled frozen producer cells allowed intensive response against tumours growing at a distant site. These treatment of groups of tumour bearing rats. The cells were findings seem to justify further exploration of IL-1 and IL-3 lysed by thawing before administration.
    [Show full text]
  • Enhancement by Interleukin 4 of Interleukin 2- Or Antibody-Induced Proliferation of Lymphocytes from Interleukin 2-Treated Cancer Patients1
    ICANCER RESEARCH 50. 1160-1 164. Februar} 15. 1990) Enhancement by Interleukin 4 of Interleukin 2- or Antibody-induced Proliferation of Lymphocytes from Interleukin 2-treated Cancer Patients1 Jonathan Treisman, Carl M. Higuchi, John A. Thompson, Steven Gillis, Catherine G. Lindgren, Donald E. Kern, Stanley R. Ridell, Philip D. Greenberg, and Alexander I efer Department of Medicine, Division of Medical Oncolog); University of Washington School of Medicine, Seattle. Has/tinglan 9X195 fJ. T., C. M. H.,J. A. T., C, G. L., D. E. K., S. R. R., P. D. G., A. F.]; and Immunex Corporation, Seattle, H'ashington 98101 [S. G.J ABSTRACT IL-2-activated cells for therapy are usually generated by ob taining PBMC from cancer patients shortly after systemic IL- Systemic interleukin 2 (IL-2) and IL-2-activated lymphocytes have 2 therapy and culturing them with IL-2 in vitro. The cells thus induced tumor regression in some cancer patients. The IL-2-activated cells have usually been generated by obtaining peripheral blood mono- generated for infusion are phenotypically and functionally het nuclear cells (PB1V1C)from cancer patients shortly after systemic IL-2 erogeneous and contain cells with LAK activity (5, 7), as well therapy and culturing them with IL-2 in vitro. In an effort to augment as other cells which may mediate or contribute to antitumor the ex vivogeneration of such cells preactivated in vivo, we examined the responses (8). In an effort to enhance the generation of such proliferative responses of PBIVIC from IL-2-treated cancer patients to cells i/i vitro, several agents which induce a proliferative re several proliferative signals including IL-2, interleukin 4 (II -4).
    [Show full text]
  • Rapid and Rigorous IL-17A Production by a Distinct
    Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology This information is current as of September 28, 2021. Peter A. Szabo, Ankur Goswami, Delfina M. Mazzuca, Kyoungok Kim, David B. O'Gorman, David A. Hess, Ian D. Welch, Howard A. Young, Bhagirath Singh, John K. McCormick and S. M. Mansour Haeryfar J Immunol published online 20 February 2017 Downloaded from http://www.jimmunol.org/content/early/2017/02/18/jimmun ol.1601366 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2017/02/18/jimmunol.160136 Material 6.DCSupplemental Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 20, 2017, doi:10.4049/jimmunol.1601366 The Journal of Immunology Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology Peter A.
    [Show full text]
  • Human Interleukin 2 Analogues That Preferentially Bind the Intermediate-Affinity Interleukin 2 Receptor Lead to Reduced Secondar
    [CANCER RESEARCH 53. 2597-2«)2. June I. 1993] Human Interleukin 2 Analogues That Preferentially Bind the Intermediate-Affinity Interleukin 2 Receptor Lead to Reduced Secondary Cytokine Secretion: Implications for the Use of These Interleukin 2 Analogues in Cancer Immunotherapy ' Keith M. Heaton,2 Grace Ju, and Elizabeth A. Grimm neiHirnneiiis ctf Tumor rìitìlogydittiGeneral Surgen; the University of Te\as M. D. Anderson Ccincer Center. Hmtuon. Te\(ts 77030 fK. M. H.. E. A. G.J. anil the Department of Inflamtiiiition/Aittotinintine Diseii\e.\. HvffnHinn-lMRfciie. Inc.. M/f/cv. New Jersey 07110 ¡G.J.¡ ABSTRACT Many of the signs and symptoms of IL-2-induced toxicity are thought to be caused by the actions of cytokines such as IL-lß. Cancer patients undergoing interleukin (IL)-2-based immunotherapy TNF-a, TNF-ß.and IFN-y released by IL-2-activated PBMC (9-14). frequently experience dose-limiting side effects believed to be caused by the actions of such cytokines as II.-I/Î,tumor necrosis factor (TNF)-a and If secretion of these secondary cytokines could be reduced, patients -ß,and interferon-y (IFN-y). Human peripheral blood mononuclear cells receiving IL-2 immunotherapy might be able to tolerate higher and (PBMC) or monocyte-dcpleted peripheral blood lymphocytes »erestim more effective doses of IL-2. ulated for up to 7 days by either of 2 IL-2 analogues (R38A or F42K) that R38A and F42K. 2 human IL-2 analogues that have altered IL-2Ra bind to the intermediate-affinity II.-2/jy receptor but have reduced abil binding domains, differ from human rIL-2 by a single amino acid ities to bind the high-affinity II -2 receptor.
    [Show full text]